Intrexon Corp (XON) CEO Randal J. Kirk Buys 1,000,000 Shares

Intrexon Corp (NYSE:XON) CEO Randal J. Kirk bought 1,000,000 shares of the business’s stock in a transaction on Friday, January 19th. The stock was bought at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Intrexon Corp (NYSE:XON) opened at $13.00 on Monday. The company has a market capitalization of $1,570.00, a price-to-earnings ratio of -11.61 and a beta of 1.33. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01. Intrexon Corp has a fifty-two week low of $10.26 and a fifty-two week high of $26.99.

Intrexon (NYSE:XON) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%. sell-side analysts predict that Intrexon Corp will post -1.06 EPS for the current fiscal year.

A number of equities research analysts have issued reports on XON shares. Zacks Investment Research cut Intrexon from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Northland Securities reiterated a “buy” rating and issued a $27.00 target price on shares of Intrexon in a research note on Friday, October 6th. Griffin Securities reiterated a “buy” rating and issued a $55.00 target price on shares of Intrexon in a research note on Friday, October 6th. JMP Securities reiterated an “outperform” rating and issued a $42.00 target price on shares of Intrexon in a research note on Thursday, October 5th. Finally, Stifel Nicolaus raised their target price on Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Intrexon has a consensus rating of “Hold” and a consensus price target of $38.50.

Several institutional investors and hedge funds have recently modified their holdings of XON. Bank of New York Mellon Corp increased its holdings in shares of Intrexon by 7.1% during the second quarter. Bank of New York Mellon Corp now owns 234,139 shares of the biotechnology company’s stock valued at $5,640,000 after purchasing an additional 15,568 shares during the period. Legal & General Group Plc increased its holdings in shares of Intrexon by 2.1% during the second quarter. Legal & General Group Plc now owns 18,843 shares of the biotechnology company’s stock valued at $454,000 after purchasing an additional 393 shares during the period. Federated Investors Inc. PA acquired a new position in shares of Intrexon during the second quarter valued at $172,000. Principal Financial Group Inc. acquired a new position in shares of Intrexon during the second quarter valued at $212,000. Finally, Alliancebernstein L.P. increased its holdings in shares of Intrexon by 0.6% during the second quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock valued at $786,000 after purchasing an additional 200 shares during the period. 77.46% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/22/intrexon-corp-xon-ceo-randal-j-kirk-buys-1000000-shares.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Insider Buying and Selling by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply